Share class: IXICO plc

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A192,668,59864,306,218 ( 69.39 %) 0 69.39 %

Major shareholders: IXICO plc

NameEquities%Valuation
Octopus Investments Ltd.
18.18 %
16,850,400 18.18 % 3 M p
BGF Investment Management Ltd.
13.91 %
12,887,000 13.91 % 2 M p
Canaccord Genuity Asset Management Ltd.
8.062 %
7,471,000 8.062 % 1 M p
Canaccord Genuity Wealth Ltd.
5.054 %
4,683,071 5.054 % 698 293 p
Amati Global Investors Ltd. (Venture Capital)
5.015 %
4,647,697 5.015 % 693 018 p
CFE (UK) Ltd.
4.163 %
3,857,566 4.163 % 575 202 p
Unicorn Asset Management Ltd.
3.87 %
3,586,000 3.87 % 534 708 p
Gresham House Asset Management Ltd.
2.651 %
2,456,868 2.651 % 366 344 p
Hargreaves Lansdown Asset Management Ltd.
2.468 %
2,287,000 2.468 % 341 015 p
City Asset Management Plc
1.541 %
1,427,860 1.541 % 212 908 p
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional68.01%
Individuals1.28%
Other0.17%
Unknown30.54%

Based on 1000 largest holdings

Geographical origin of shareholders

United Kingdom 67.82%
Individuals 1.28%
United States 0.16%
Luxembourg 0.14%
Netherlands 0.03%
Switzerland 0.02%

Based on 1000 largest holdings

Logo IXICO plc
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
Employees
81
More about the company